CLINICAL TRIALS PROFILE FOR PALIPERIDONE PALMITATE
✉ Email this page to a colleague
All Clinical Trials for paliperidone palmitate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00073320 ↗ | Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2003-08-01 | The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal). |
| NCT00074477 ↗ | Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2003-10-01 | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings. |
| NCT00101634 ↗ | Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2004-12-01 | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings. |
| NCT00111189 ↗ | A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. | Completed | Janssen-Cilag International NV | Phase 3 | 2005-02-01 | The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings. |
| NCT00111189 ↗ | A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2005-02-01 | The purpose of this study is to evaluate the efficacy of paliperidone palmitate compared with placebo in the prevention of recurrence of the symptoms of schizophrenia and to assess the safety and tolerability of paliperidone palmitate in patients with stable and symptomatic schizophrenia. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings. |
| NCT00119756 ↗ | A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2005-06-01 | The purpose of this study is to evaluate the safety and tolerability of intramuscular injections (to the buttocks or to the shoulders) of paliperidone palmitate in patients with schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for paliperidone palmitate
Condition Name
Clinical Trial Locations for paliperidone palmitate
Trials by Country
Clinical Trial Progress for paliperidone palmitate
Clinical Trial Phase
Clinical Trial Sponsors for paliperidone palmitate
Sponsor Name
